Bromfenac Ophthalmic Solution 007  A Review of

Authors: Sheridan M Hoy

Publish Date: 2015/07/16

Volume: 35, Issue: 8, Pages: 525-529

PDF Link

Abstract

The nonsteroidal antiinflammatory drug bromfenac has recently been reformulated with a lower pH to facilitate a reduction in the concentration of bromfenac to 007  while ensuring an ocular bioavailability similar to that of the 009  formulation Bromfenac ophthalmic solution 007  hereafter referred to as bromfenac 007  Prolensa® is a oncedaily topical ophthalmic solution available in the USA and Canada for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery In an integrated analysis of two multicentre phase III studies bromfenac 007  was significantly more effective than placebo in reducing ocular inflammation and pain In these studies bromfenac 007  was well tolerated with significantly lower incidences of adverse events and adverse events affecting the study eye than with placebo The most common adverse events in the study eye eye pain anterior chamber inflammation foreign body sensation photophobia conjunctival hyperaemia and corneal oedema occurred in numerically fewer bromfenac 007  than placebo recipients Thus current evidence suggests oncedaily bromfenac 007  extends the treatment options currently available for the management of postoperative inflammation and pain following cataract surgeryThe preparation of this review was not supported by any external funding During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on this article Changes resulting from comments received were made by the author on the basis of scientific and editorial merit Sheridan Hoy is a salaried employee of Adis/Springer

Keywords: